COMP <GO>
SUPN vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
Supernus Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: SUPN 5
— UNH 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SUPN
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
balance-sheet
4.84
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 88.57% | +1.03 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 11.47% | -15.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 6.48% | -4.59 | UNH | /fcf-yield <GO> |
| Operating Margin | -8.70% | 4.82% | -13.52 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 3.14% | -8.54 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 6.46% | +2.14 | SUPN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.84 | 3.12 | +1.72 | SUPN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.74% | -0.24 | SUPN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 56.0 | -5.06 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | SUPN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 17.1x | +4.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $364.66B | -$362.23B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | UNH REV | SUPN GROSS % | UNH GROSS % | SUPN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $447.57B | 89.6% | 88.7% | $46.0M | $16.07B |
| FY 2024 | $661.8M | $400.28B | 88.2% | 88.3% | $171.2M | $20.70B |
| FY 2023 | $607.5M | $371.62B | 44.0% | 89.6% | $83.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
UNH // BETA 0.33